BioTech
High Hopes on Ariad (ARIA, MRK)
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is seeing elevated trading today after a presentation and ahead of earnings. The difference here is that Ariad’s increased trading is in both the stock and in the bonds.
Joe Kunkle of OptionsHawk.com noted, “implied volatility is 10% higher to 87.8% as shares gain 2.7%, 4,140 calls trading, [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
More Drug and BioHealth Dividends (MRX, WCRX, AMGN, MRK, PFE, PPH, BBH)
Medicis (NYSE: MRX), a specialty pharmaceutical company in treatments of dermatological and aesthetic conditions, has the talk going again about dividends in the drug and biotech sector. The company declared a quarter-end cash quarterly dividend of $0.06 payable on April 30, 2010 for holders of record at the close of business on April 1, 2010. [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI)
Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009. The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB). Abbott Laboratories (NYSE: ABT) announced last night that it entered into a definitive agreement for $27.00 per share in a cash buyout. [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
EDAP TMS, Back on the Map (EDAP)
EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company’s stock is soaring after the company was granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device by the Japanese Administration. Because this market is still under-served, we wanted to look [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Amylin & Friends Brace for Diabetes Review (AMLN, LLY, ALKS)
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week. This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes. The date had been moved due [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)
The biotech and biohealth universe is changing in size. In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion. At one point there were only about 10 or 11 in our [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
When Biotech Layoffs Come (XNPT)
When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee. That leaves more income and ultimately brings more dividends down the road. But biotech firms are far from being thought of in the [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)
BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors. But sometimes there is a much larger bit of data either north of the border or in Europe. There is a company called Resverlogix Corp. which trades in Canada under the ticker ‘RVX’ and the stock also trades in the US [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)
Today’s price moves in the biotech sector are quite different from what we saw earlier this week. A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week. So much that other investors were going back over buyout candidate notes. We also gave a list of [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)
Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion. The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday.
The company did note that a separate Phase 3 safety study demonstrated [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
More Biotech Buyout or M&A Targets (OSIP, VRTX, AUXL, ITMN, HGSI, CELG, DNDN, ENZN, FACT, PBE, XBI)
After today’s hostile Astellas offer for OSI Pharmaceuticals (NASDAQ: OSIP), we have investors and traders alike looking for ‘the next takeover target’ in biotech. Buy now you know that there are many pitfalls in simply looking for biotech stocks to buy because they will be taken over. We have taken a look through our own [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Hostile Mergers Back in Biotech (OSIP)
Mergers are back in biotech…. Astellas Pharma Inc., a global pharmaceutical company in Japan, announced that it will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP). The direct tender is nothing short of a hostile merger after Astellas said that OSI has refused to discuss terms.
The [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Generic Drug Wars… Is Dr. Reddy’s The Answer? (RDY, TEVA, GSK)
Generic drugs are just one of the many combined issues that are coming front and center in the world of healthcare reform. Frankly this is not a new notion. Not all. This weekend came a feature in Barron’s “Asian Trader: Pill Maker That’s Set To Pop” calling Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) of India [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
InterMune Volatility Compression (ITMN)
InterMune Inc. (NASDAQ: ITMN) has shown some very interesting options trading, and the trading looks to be a bet against all that huge volatility we have seen.
Joe Kunkle of OptionsHawk.com noted:
ITMN with a 2,000X4,000X2,000 contract butterfly call spreads at the March $25/$30/$35 strikes. This trade bets on volatility to collapse, which will happen after the [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Two key Analyst Call in BioHealth Space (DNDN, HGSI)
We have seen two very key biotech analyst calls this morning, and shares of both are responding. Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences (NASDAQ: HGSI) were both given positive brokerage initiations this morning.
Dendreon Corp. (NASDAQ: DNDN) is seeing gains this morning after the stock was started as “Overweight” and $46 target at JPMorgan. [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Buyout Rumors Resurface in Biotech, Maybe (DNDN, MYGN)
Sometimes it is the action seen in stock options gets traders moving more than the action in the stock. With more commentators on CNBC and other media outlets talking about ‘elevated options trading seen in…’ it gets even more on alert. From our best read today, that seems to be the case in Dendreon Corp. [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Rigel Attacks Rheumatoid Arthritis with AstraZeneca (RIGL, AZN)
Rigel Pharmaceuticals (NASDAQ: RIGL) may be the biotech winner this Tuesday. The company has signed a pact with AstraZeneca (NYSE: AZN) which could ultimately bring in about $1.25 billion if all targets are met. This pact is a licensing agreement for Rigel’s rheumatoid arthritis drug R788 or fostamatinib disodium.
Rigel said last year that its R788 [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Dividends Coming In Biotech & Pharma? (WCRX, AMGN, MRK, PFE, PPH, BBH)
Many investors have been focusing on the number of dividend raises we have so far seen since the end of December. It is the perfect vote of confidence issued by a company, much more so than a share buyback plan. The dividend means “we will be able to this rate over and over” for investors. [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
Cell Therapeutics Facing Tougher FDA (CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is getting clipped on Pixantrone this morning. The company was told by the FDA that there is limited clinical data on its proposed cancer drug, and that there were higher side effects and higher death incidents. Unfortunately, this comes ahead of a panel review date that is set for Wednesday, [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
New Restless Leg Syndrome Review for XenoPort (XNPT, GSK)
XenoPort, Inc. (NASDAQ: XNPT) has a big day coming for its GSK1838262/XP13512 (gabapentin enacarbil) next week. The company has a date of February 9 for an FDA Prescription Drug User Fee Act (PDUFA) decision on its Horizant. This is the dated goal for the company’s New Drug Application for Horizant for the treatment of moderate-to-severe [...]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech
WPS Video Board
Most played videos
- ACTC - Dr. Robert Lanza from Advanced Cell Technology Inc. with Barbara Walters - Stem Cell Research
- EVII - Ev Innovations New Products (Electric Vehicles)
- How to Trade Triangle Chart Patterns Like a Pro Part 1
- Cramer on the UltraShort Financials (SKF)
- Biofuels scandal + food prices
- PBCT - People's United Fiancial | CEO Interview | Profitable, Growing, Acquiring
- Sub-prime crisis - what next in banking?
- A look at trendlines using candlestick charting
- How to Trade the Wedge Chart Pattern Like a Pro Part 1
- Inside Look: Madoff's Ponzi Scheme
Most downloaded
- EVII - Ev Innovations New Products (Electric Vehicles)
- VLY - Valley National Bancorp | Remains Strong | CEO Interview
- Future of the Pharmaceutical Industry
- Sub-prime crisis - what next in banking?
- Biofuels scandal + food prices
- ACTC - Dr. Robert Lanza from Advanced Cell Technology Inc. with Barbara Walters - Stem Cell Research
- Cramer on the UltraShort Financials (SKF)
- Inside Look: Madoff's Ponzi Scheme
- A look at trendlines using candlestick charting
- How to Trade the Wedge Chart Pattern Like a Pro Part 1
Top videos
- ACTC - Dr. Robert Lanza from Advanced Cell Technology Inc. with Barbara Walters - Stem Cell Research
- EVII - Ev Innovations New Products (Electric Vehicles)
- How to Trade Triangle Chart Patterns Like a Pro Part 1
- Cramer on the UltraShort Financials (SKF)
- Biofuels scandal + food prices
- PBCT - People's United Fiancial | CEO Interview | Profitable, Growing, Acquiring
- Sub-prime crisis - what next in banking?
- A look at trendlines using candlestick charting
- How to Trade the Wedge Chart Pattern Like a Pro Part 1
- Inside Look: Madoff's Ponzi Scheme
Latest videos
- ACTC - Dr. Robert Lanza from Advanced Cell Technology Inc. with Barbara Walters - Stem Cell Research
- Biofuels scandal + food prices
- Sub-prime crisis - what next in banking?
- Future of the Pharmaceutical Industry
- VLY - Valley National Bancorp | Remains Strong | CEO Interview
- PBCT - People's United Fiancial | CEO Interview | Profitable, Growing, Acquiring
- EVII - Ev Innovations New Products (Electric Vehicles)
- How to Trade Triangle Chart Patterns Like a Pro Part 1
- How to Trade the Flag/Pennant Patterns Like a Pro Part2
- How to Trade the Wedge Chart Pattern Like a Pro Part 1
Stocks
- Examiner: Lehman Torpedoed Lehman
- Air China to Raise $952 Million
- India's ONGC in Talks With Russia
- Pink Floyd Wins Downloads Suit
- Google Nears Decision on China Censoring
- LibertyPointe: 27th Bank Failure of Year
- Buffett's Pay: Steady at $175,000
- Data Theft Hits HSBC Clients
- Farallon Regroups After Knockdown
- AIG Workers to Give Up $45 Million to Uncle Sam
- Citi Says It Is Poised For Sustained Profits
- Hearst Tries Hand at Apps
- Gamble on Financial Overhaul
- U.S. Weighs Stricter Car-Safety Rules
- NYSE Questions Black & Decker
Who's new
OTCBB Stock News
- TimelessWealth.net: OTC Market Wire: Cascadia Investments, Inc. (PINKSHEETS ... - Insurance News Net (press release)
- Laxai Pharma purchases OSR Solutions CRO for $3.6M - News-Medical.net
- InvestorIdesa.com: Silver and Gold Exploration Company, Tombstone Exploration ... - Online PR News (press release)
- OTCBB AREN Announces Appointments to the Board of Directors - EON: Enhanced Online News (press release)
- Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results - Genetic Engineering News (press release)
- Del Global Technologies Reports Fiscal 2010 Second Quarter Financial Results - EON: Enhanced Online News (press release)
- Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results - EON: Enhanced Online News (press release)
OTC Pink Sheet Stock News
- Shiseido Completes Tender Offer For Bare Escentuals - Update - RTT News
- Top Penny Stock Gainers Today include ZANE, SSEV, SYMBA - TransWorldNews (press release)
- General Growth Properties Files Application To List Common Stock On NYSE ... - RTT News
- Visteon Turns To Q4 Profit - Quick Facts - RTT News
- Nebula Stocks In Jointly with Lightspeed Stocks Presents HSCO.PK News Update - Earthtimes (press release)
- Nebula Stocks LLC: Nebula Stocks In Jointly with Lightspeed Stocks Presents ... - Trading Markets (press release)
- Nebula Stocks In Jointly with Lightspeed Stocks Presents HSCO.PK News Update - Emailwire
- Samsung Electronics Receives Board Approval To Buy Samsung Digital Imaging ... - RTT News
- Nestle FY09 Profit Declines - Update - RTT News
Counter
- Site Counter: 493,313
- Unique Visitor: 13,203
- Registered Users: 1,444
- Unregistered Users: 0
- Published Nodes: 1,927
- Unpublished Nodes: 6
- Server IP: 69.175.89.42
- Your IP: 38.107.191.88
- Since: 2009-04-27 01:09

